Pfizer and BioNTech are expected to apply for an emergency license for their covid-19 vaccine to children aged six months to five years from today at the US Food and Drug Administration (FDA), according to a Washington paper report. Post.
Covid-19 vaccines for children under 5 may be available as early as late February who have knowledge of the case.
According to the newspaper, the FDA asked the companies to submit the application so that the regulators can start examining the data on the scheme of the two installments.
“The idea is to go ahead and start examining the two doses,” the Washington Post article said. if we waited until the data for the third dose were collected “.
Pfizer announced in January that it was awaiting the latest data from clinical trials in children under the age of 5 by April, after changing its research to give a third dose of the vaccine to all children under the age of 5 at least eight weeks after second.
The company made this correction in the study because it appeared that children aged 2 to 4 years who were given two doses of 3 micrograms of the drug did not have the same immune response as older children who were given a higher dose.
I am Derek Black, an author of World Stock Market. I have a degree in creative writing and journalism from the University of Central Florida. I have a passion for writing and informing the public. I strive to be accurate and fair in my reporting, and to provide a voice for those who may not otherwise be heard.